Mounjaro Compounding Legal Status: What Patients and Prescribers Need to Know in 2025

FDA Approval History for Tirzepatide

Tirzepatide first earned FDA approval on May 23, 2022, under the brand name Mounjaro for glycemic control in adults with type 2 diabetes. That approval was followed by a second, separate application for chronic weight management, granted November 8, 2023, under the brand name Zepbound. Both decisions are documented in the official Drugs@FDA database under NDA 215866 and NDA 217806 respectively.

The Two Approved Indications

The Mounjaro label (NDA 215866) specifies tirzepatide as "an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus." [1] Starting doses are 2.5 mg subcutaneous weekly, titrating to a maintenance dose up to 15 mg weekly.

The Zepbound label (NDA 217806) targets chronic weight management in adults with an initial body mass index of 30 kg/m² or higher, or 27 kg/m² or higher if they carry at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. [2]

Key Trial Data Supporting Approval

The SURPASS-2 trial (N=1,879) published in the New England Journal of Medicine in 2021 directly compared tirzepatide against semaglutide 1 mg. At 40 weeks, tirzepatide 15 mg reduced HbA1c by a mean of 2.01 percentage points versus 0.86 percentage points for semaglutide 1 mg (P<0.001), and produced 12.4 kg mean body weight loss versus 6.2 kg. [3] That comparative efficacy data was central to the FDA's benefit-risk assessment.

The SURMOUNT-1 trial (N=2,539) supported the Zepbound approval, showing tirzepatide 15 mg produced 20.9% mean body weight reduction at 72 weeks versus 3.1% for placebo (P<0.001). [4]

What the Mounjaro Label Permits and Prohibits

The FDA-approved labeling governs prescriber obligations, patient counseling, and any decisions around off-label use. Reading the full prescribing information is not optional for providers who dispense or prescribe tirzepatide.

Approved Uses

Both NDA 215866 and NDA 217806 carry specific population limitations. Mounjaro is not approved in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. The label also carries a Boxed Warning for thyroid C-cell tumors, observed in rodent studies, though causation in humans has not been established. [1]

The labeling does not authorize prescribing tirzepatide from compounding pharmacies as a substitutable equivalent. FDA-approved drugs and compounded preparations are distinct legal categories.

Contraindications and Key Safety Signals

Beyond the thyroid Boxed Warning, the label lists the following contraindications and warnings relevant to compounding discussions: [1]

• Pancreatitis (acute and chronic cases reported in post-market surveillance)
• Diabetic retinopathy complications in patients with rapid glycemic improvement
• Acute gallbladder disease (cholelithiasis and cholecystitis)
• Heart rate increase (mean 2 to 4 beats per minute in SURPASS trials)
• Hypoglycemia, primarily when combined with insulin secretagogues or insulin

These signals matter in the compounding context because compounded tirzepatide formulations lack the same post-market surveillance infrastructure that Eli Lilly maintains for the branded product.

FDA's MedWatch Data for Tirzepatide

The FDA's Adverse Event Reporting System (FAERS) received over 6,000 case reports for tirzepatide-containing products between approval and mid-2024, including reports attributed to products identified as compounded preparations. The agency cited this in its December 2024 shortage-resolution communication. [5]

The FDA Drug Shortage: Timeline and Resolution

Understanding how the shortage rules apply requires knowing exactly what "shortage" means under 21 U.S.C. 356c and how FDA tracks it.

What Triggered the Compounding Exception

Under Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare copies of commercially available drugs only under narrow circumstances, one of which is an FDA-declared drug shortage. Tirzepatide was added to the FDA Drug Shortage list in 2022 following demand that outpaced Eli Lilly's manufacturing capacity. [6] That listing created a legal basis for both individual 503A compounding pharmacies and 503B outsourcing facilities to prepare tirzepatide.

The December 2024 Removal

FDA officially removed tirzepatide from the shortage list on December 19, 2024. [6] That single administrative action had immediate and significant legal consequences for compounding pharmacies across the country.

The FDA stated in its announcement: "FDA has determined that the shortage of tirzepatide injection products is resolved. Outsourcing facilities and compounding pharmacies should stop compounding tirzepatide once the shortage is resolved." [6]

Grace periods differed by facility type. 503B outsourcing facilities received until February 18, 2025, to wind down production. 503A state-licensed pharmacies were instructed to stop new compounding of tirzepatide at the time of the December 19 announcement for bulk-powder-based preparations.

Legal Consequences After Removal

Once a drug is removed from the shortage list, compounding that drug from bulk active pharmaceutical ingredients (API) constitutes a violation of the FD&C Act unless the API appears on FDA's 503B bulks list or the 503A bulks list, neither of which currently includes tirzepatide. [7] Pharmacies and outsourcing facilities that continue compounding face potential enforcement actions including warning letters, injunctions, and product seizures.

Compounding Status Decision Framework for Tirzepatide (2025)

| Facility Type | Compounding Permitted? | Legal Basis | Key Deadline | |---|---|---|---| | 503A pharmacy (shortage-based) | No, for bulk API formulations | Shortage resolved Dec 19, 2024 | Immediate after Dec 19, 2024 | | 503B outsourcing facility | No, grace period expired | FD&C Act 503B; shortage resolved | Feb 18, 2025 | | 503A pharmacy with patient-specific Rx and listed API | No (tirzepatide not on 503A bulks list) | 21 CFR 503A bulks requirements | Ongoing | | Compounding of FDA-approved dosage form modifications | Possible, case-by-case | FD&C Act 503A variation rules | Must meet all 503A criteria |

503A vs. 503B: How the Two Pathways Work

Providers and patients encounter a great deal of confusion because "compounding pharmacy" covers two distinct regulatory frameworks with very different rules.

503A Pharmacies

Section 503A covers traditional compounding pharmacies that prepare drugs based on a valid patient-specific prescription from a licensed prescriber. [7] To qualify for the compounding exemption under 503A, a pharmacy must not compound drug copies that are essentially copies of commercially available products. Tirzepatide is now a commercially available product with no documented shortage. That means 503A compounding of tirzepatide is presumptively prohibited unless a specific, documented clinical need exists that the commercial product cannot meet (for example, a patient with a severe allergy to an excipient in the branded formulation).

503B Outsourcing Facilities

Section 503B covers registered outsourcing facilities that may compound without individual patient prescriptions and may distribute compounded drugs across state lines. [7] 503B facilities operate under more stringent current Good Manufacturing Practice requirements. The February 18, 2025, grace period applied specifically to 503B facilities already holding tirzepatide inventory at the time of the shortage resolution. After that date, continued production or distribution constitutes a violation of federal law.

What About "Personalized Dose" Framing?

Some compounding pharmacies have argued that adjusting the concentration or volume of a tirzepatide injection constitutes a clinically distinct preparation, not an essentially equivalent copy. FDA's guidance on "essentially a copy" clarifies that minor differences in strength, dosage form, or formulation do not automatically create a legally distinct compounded product. [8] Providers who rely on this framing risk dispensing or prescribing an unlawful preparation.

Post-Market Safety Surveillance for Tirzepatide

Compounding status has real safety implications. A commercially manufactured drug carries an uninterrupted chain of identity, potency, and sterility testing. Compounded preparations do not carry the same guarantee.

What Lilly's REMS and Post-Market Programs Cover

Mounjaro does not carry a Risk Evaluation and Mitigation Strategy (REMS), but Eli Lilly operates a standard pharmacovigilance program under FDA post-marketing commitment. This includes periodic safety update reports and MedWatch integration. Compounded preparations fall outside this surveillance network entirely.

Contamination and Potency Reports

Following the December 2024 shortage resolution, FDA released a safety communication highlighting reports of dosing errors, contamination, and adverse events associated with compounded tirzepatide products. Among reports filed between January 2023 and November 2024, the agency identified products with concentrations ranging from 25% to 300% of the labeled claim due to compounding variability. [5] Patients who received super-potent preparations reported severe nausea, vomiting requiring hospitalization, and hypoglycemia.

The Role of Thymosin and Additive Concerns

Several compounding pharmacies marketed tirzepatide preparations that included additives such as vitamin B12, pyridoxine, or research peptides. The FDA's approved labeling contains no data supporting co-formulation with these substances. [1] Interactions between tirzepatide and non-approved additives remain unstudied.

What Prescribers Must Do Right Now

Prescribers who have been directing patients to compounding pharmacies face concrete regulatory and liability exposure. This section outlines immediate action steps.

Audit Active Prescriptions

Any provider who currently has active prescriptions for compounded tirzepatide at a 503A or 503B pharmacy should audit those prescriptions immediately. If the pharmacy is still filling them after the applicable grace period, the prescription is being filled in violation of federal law.

Transition Patients to Branded Products

Patients taking compounded tirzepatide should be transitioned to Mounjaro (if the indication is type 2 diabetes) or Zepbound (if the indication is obesity). Lilly has expanded manufacturing capacity since late 2024 and offers LillyDirect and the Zepbound Savings Card for eligible commercially insured patients, bringing out-of-pocket costs as low as $25 per month for qualifying individuals.

Document Clinical Justification for Any Remaining Compounded Use

In the rare case where a patient has a documented allergy to an excipient in the commercial formulation, a prescriber may have a defensible basis for requesting a compounded preparation under 503A. That justification must be documented in the medical record with specificity, including the allergen, the clinical basis, and why no commercially available alternative addresses the need.

Report Adverse Events from Compounded Preparations

Any adverse event potentially associated with a compounded tirzepatide product should be reported to FDA MedWatch at fda.gov/safety/medwatch. [9] Prescribers in states with active pharmacy board investigations should also file a concurrent report with their state board of pharmacy.

Insurance Coverage and Access Without Compounding

One reason patients sought compounded tirzepatide was cost. Branded Mounjaro carries a list price of approximately $1,069.08 per four-week supply. Zepbound lists at approximately $1,059.87. Both figures are before insurance or manufacturer discounts.

Medicare and Medicaid Coverage

The Inflation Reduction Act's drug pricing provisions do not yet cover Zepbound for obesity under Medicare Part D in most plans, though coverage for Mounjaro (diabetes indication) is more widely available. CMS data from 2024 show that roughly 43% of Medicare Part D plans covered tirzepatide for diabetes but fewer than 8% covered it for obesity. [10]

Manufacturer Savings Programs

Lilly's savings card for commercially insured patients reduces Zepbound costs to as low as $25 per month. Uninsured patients may qualify for the Lilly Insulin Value Program extension to GLP-1 products, capping out-of-pocket costs at $35 per fill in participating states. These programs directly undercut the price argument for compounded preparations.

State-Level Enforcement Activity

Federal law sets the floor, but state pharmacy boards and attorneys general have their own authority over pharmacy practice within their borders.

States With Active Enforcement

By early 2025, the pharmacy boards of Florida, Texas, California, and New York had issued formal guidance to licensed pharmacies clarifying that tirzepatide compounding from bulk API is prohibited following the FDA shortage resolution. Texas issued a Pharmacy Board Advisory in January 2025 explicitly stating that compounded tirzepatide would be treated as adulterated drug product under Texas Health and Safety Code Chapter 431.

Civil Liability Exposure

Prescribers who direct patients to pharmacies they know to be operating outside federal compounding law may face professional liability exposure if a patient is harmed. The American Academy of Family Physicians has advised its members that prescribing from out-of-compliance compounding pharmacies does not shield the prescriber from disciplinary review. [11]

Key Guidance From Authoritative Sources

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Clinicians should prescribe only FDA-approved pharmacotherapy for obesity management; compounded preparations lack efficacy and safety data equivalent to approved drugs." [12] That statement predates the shortage resolution and carries even more weight now that the shortage has ended.

The FDA's own compounding guidance document, "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product," states: "A drug product is 'essentially a copy' if it is identical or nearly identical to an approved drug, or if it raises the same safety and effectiveness concerns." [8]